Education
About Us
Working with TipRanks
Follow Us
Intensity Therapeutics, Inc. (INTS)
NASDAQ:INTS
INTS Stock Chart & Stats
$0.25
-$0.05(-2.51%)
At close: 4:00 PM EST
$0.25
-$0.05(-2.51%)
Day’s Range― - ―
52-Week Range$0.19 - $3.44
Previous CloseN/A
Volume52.56K
Average Volume (3M)5.11M
Market Cap
$11.67M
Enterprise Value$3.70M
Total Cash (Recent Filing)$2.22M
Total Debt (Recent Filing)$125.00K
Price to Earnings (P/E)―
Beta0.08
Next Earnings
Nov 18, 2025EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding49,055,460
10 Day Avg. Volume8,790,984
30 Day Avg. Volume5,112,980
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.32
Enterprise Value/Revenue154.23
Enterprise Value/Gross Profit-462.69
Enterprise Value/Ebitda-0.29
Forecast
1Y Price Target
$2.25Price Target Upside800.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressDOR data bodes well for the Phase 3 sarcoma study.
Market PotentialThe combination of improved safety, targeted therapy, and adaptive immune stimulus could enable INT230-6 to capture a significant portion of the solid tumor therapy market.
Treatment InnovationDeveloping a disruptive treatment for solid tumors.
Bears Say
Equity OfferingThe company announced a registered direct equity offering with gross proceeds of approximately $3M.
Financial PerformanceThe company reported no revenues, and a net loss of $0.25 per diluted share, compared to our estimate of no revenues and a net loss of $0.16 per diluted share.
Intensity Therapeutics, Inc. News
INTS FAQ
What was Intensity Therapeutics, Inc.’s price range in the past 12 months?
Intensity Therapeutics, Inc. lowest stock price was $0.18 and its highest was $3.44 in the past 12 months.
What is Intensity Therapeutics, Inc.’s market cap?
Intensity Therapeutics, Inc.’s market cap is $11.67M.
When is Intensity Therapeutics, Inc.’s upcoming earnings report date?
Intensity Therapeutics, Inc.’s upcoming earnings report date is Nov 18, 2025 which is in 18 days.
How were Intensity Therapeutics, Inc.’s earnings last quarter?
Intensity Therapeutics, Inc. released its earnings results on Aug 07, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.17 by $0.04.
Is Intensity Therapeutics, Inc. overvalued?
According to Wall Street analysts Intensity Therapeutics, Inc.’s price is currently Undervalued.
Does Intensity Therapeutics, Inc. pay dividends?
Intensity Therapeutics, Inc. does not currently pay dividends.
What is Intensity Therapeutics, Inc.’s EPS estimate?
Intensity Therapeutics, Inc.’s EPS estimate is -0.06.
How many shares outstanding does Intensity Therapeutics, Inc. have?
Intensity Therapeutics, Inc. has 49,055,460 shares outstanding.
What happened to Intensity Therapeutics, Inc.’s price movement after its last earnings report?
Intensity Therapeutics, Inc. reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.17. Following the earnings report the stock price went up 8%.
Which hedge fund is a major shareholder of Intensity Therapeutics, Inc.?
Currently, no hedge funds are holding shares in INTS
Company Description
Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc. (INTS) is a clinical-stage biotechnology company focused on developing innovative cancer treatments. The company specializes in the research and development of immune-based therapies designed to enhance the effectiveness of existing anti-cancer treatments. Intensity Therapeutics aims to improve patient outcomes by utilizing its proprietary DfuseRxSM technology, which involves direct injection of therapeutic agents into tumors, thereby increasing the immune system's ability to combat cancer cells.
INTS Stock 12 Month Forecast
Average Price Target
$2.25
▲(800.00% Upside)
Technical Analysis
Biodexa Pharmaceuticals
―
Q/C Technologies
―
Salarius Pharmaceuticals
―
Scinai Immunotherapeutics
―
Oragenics
―
Ownership Overview
0.18% Insiders
0.23% Mutual Funds
3.13% Other Institutional Investors
96.41% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---